Thermo Fisher Scientific, Shanghai, China.
Advanced Electrophoresis Solution Ltd., Cambridge, Canada.
Anal Biochem. 2023 Jan 1;660:114961. doi: 10.1016/j.ab.2022.114961. Epub 2022 Oct 29.
Imaging capillary isoelectric focusing (icIEF) technology has been becoming the gold criteria of monitoring monoclonal antibody (mAb) charge heterogeneity that is one of the major product-related variants in recombinant biopharmaceuticals, since the first commercial instrument developed twenty years ago. However, the protein identification in icIEF separation is just based on isoelectric point (pI) measurement of protein. Although high resolution mass spectrometry (HRMS) is currently the most powerful means of qualitative protein analysis, traditional icIEF cannot compatibly be used in conjunction with MS due to the use of less volatile reagents. In addition, protein heterogeneity characterization in depth such as peptide mapping by high performance liquid chromatography (HPLC) requires the focused protein bands to be collected as fractions after the icIEF separation, which is a great challenge in biopharmaceutical discovery. In this work, pembrolizumab was employed as targeting mAb (a highly selective anti-PD-1 humanized mAb), an integrated icIEF platform was developed including analytical profiling, MS coupling and fraction collections for charged variant preparation. Multiple operation modes can be rapidly and flexibly switched just by changing customized capillary separation cartridges without more configurations. Main component, four acidic variants (A1-A4) and three basic variants (B1-B3) were baseline separated then directly detected by icIEF-HRMS online coupling for rapid screening of intact protein heterogeneity where reliable and accurate molecular weight of protein charged variants were obtained. Next, by installing preparative capillary separation cartridge, fractions of major charge variants (A2-3 and B1-2) and main component were collected for following LC-MS peptide mapping characterization. The whole workflow of icIEF-based MS strategy for protein heterogeneity is straight forward, reliable and accurate, which provides a comprehensive and revolutionary technology for protein drug quality control (QC) monitoring, MS coupling for fingerprinting intact protein and HPLC-MS peptide mapping in depth.
成像毛细管等电聚焦 (icIEF) 技术自二十年前第一台商业仪器问世以来,已成为监测单克隆抗体 (mAb) 电荷异质性的金标准,电荷异质性是重组生物制药中主要的与产品相关的变异之一。然而,icIEF 分离中的蛋白质鉴定仅基于蛋白质的等电点 (pI) 测量。尽管高分辨率质谱 (HRMS) 是目前定性蛋白质分析最有力的手段,但由于使用了挥发性较低的试剂,传统的 icIEF 无法与 MS 兼容使用。此外,如高效液相色谱 (HPLC) 肽图分析等蛋白质异质性的深入特征分析需要在 icIEF 分离后将聚焦的蛋白质条带作为馏分收集,这在生物制药发现中是一个巨大的挑战。在这项工作中,我们使用 pembrolizumab 作为靶向 mAb(一种高度选择性的抗 PD-1 人源化 mAb),开发了一种集成的 icIEF 平台,包括分析 profiling、MS 耦合和馏分收集,用于带电变体的制备。通过更换定制化的毛细管分离试剂盒,可以快速灵活地切换多种操作模式,而无需更多的配置。主要成分,四个酸性变体 (A1-A4) 和三个碱性变体 (B1-B3) 被基线分离,然后通过 icIEF-HRMS 在线耦合直接检测,用于快速筛选完整蛋白质的异质性,从而获得可靠准确的蛋白质带电变体分子量。接下来,通过安装制备毛细管分离试剂盒,收集主要带电变体 (A2-3 和 B1-2) 和主要成分的馏分,用于随后的 LC-MS 肽图特征分析。基于 icIEF 的 MS 策略的蛋白质异质性的整个工作流程简单、可靠和准确,为蛋白质药物质量控制 (QC) 监测、MS 指纹分析和 HPLC-MS 肽图深入分析提供了一种全面的革命性技术。